- Home
- JAGX vs APVO Comparison
JAGX vs APVO Comparison
Compare JAGX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- APVO
- Stock Information
- Founded
- JAGX 2013
- APVO 2016
- Country
- JAGX United States
- APVO United States
- Employees
- JAGX N/A
- APVO N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- JAGX Health Care
- APVO Health Care
- Exchange
- JAGX Nasdaq
- APVO Nasdaq
- Market Cap
- JAGX 3.5M
- APVO 4.1M
- IPO Year
- JAGX N/A
- APVO N/A
- Fundamental
- Price
- JAGX $2.70
- APVO $3.00
- Analyst Decision
- JAGX Strong Buy
- APVO Strong Buy
- Analyst Count
- JAGX 1
- APVO 1
- Target Price
- JAGX $60.00
- APVO $5,920.00
- AVG Volume (30 Days)
- JAGX 86.0K
- APVO 6.7M
- Earning Date
- JAGX 08-12-2025
- APVO 08-07-2025
- Dividend Yield
- JAGX N/A
- APVO N/A
- EPS Growth
- JAGX N/A
- APVO N/A
- EPS
- JAGX N/A
- APVO N/A
- Revenue
- JAGX $11,552,000.00
- APVO N/A
- Revenue This Year
- JAGX $22.41
- APVO N/A
- Revenue Next Year
- JAGX $30.00
- APVO N/A
- P/E Ratio
- JAGX N/A
- APVO N/A
- Revenue Growth
- JAGX 13.93
- APVO N/A
- 52 Week Low
- JAGX $2.43
- APVO $2.81
- 52 Week High
- JAGX $110.75
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- JAGX 33.71
- APVO 34.83
- Support Level
- JAGX $2.53
- APVO $2.89
- Resistance Level
- JAGX $2.65
- APVO $3.20
- Average True Range (ATR)
- JAGX 0.18
- APVO 0.27
- MACD
- JAGX 0.14
- APVO 0.24
- Stochastic Oscillator
- JAGX 31.03
- APVO 10.63
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.